SCHEMBL1306587

SCHEMBL1306587

O=CN1CCC(N2CCOCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL3 Q96JM7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 1/20 0.39
OPRL1 P41146 2/20 0.38
HSD11B1 P28845 1/20 0.37
ACHE P22303 1/20 0.37
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
KDM1A O60341 1/20 0.36
MAOB P27338 1/20 0.36
CBX7 O95931 1/20 0.35
CDYL2 Q8N8U2 1/20 0.35
CDYL Q9Y232 1/20 0.35
CDY1; CDY1B Q9Y6F8 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
EPHX2 P34913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31693240 0.98 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL3L3MBTL1LMNAOPRL1
Hydrochloric Acid SCHEMBL31693414 0.98 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL3L3MBTL1LMNAOPRL1
SCHEMBL1306429 0.88 SMN1; SMN2 (0.42) SMN1; SMN2L3MBTL3L3MBTL1LMNAOPRL1
SCHEMBL3631668 0.88 SMN1; SMN2 (0.42) SMN1; SMN2L3MBTL3L3MBTL1LMNAOPRL1
SCHEMBL29336538 0.83 HRH3 (0.41) SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL26091356 0.81 SMN1; SMN2 (0.40) SMN1; SMN2L3MBTL3L3MBTL1LMNAOPRL1
SCHEMBL27979100 0.81 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL3L3MBTL1LMNAOPRL1
SCHEMBL1306349 0.80 MEN1 (0.44) L3MBTL3L3MBTL1KDM4E
SCHEMBL28452884 0.80 L3MBTL3 (0.41) L3MBTL3L3MBTL1KDM4E
SCHEMBL19775351 0.79 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024035194-A1 NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME 환인제약 주식회사 2024-02-15 WO claimed
WO-2023220396-A1 METHODS OF TREATMENT USING A DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A (DYRK1A) INHIBITOR FRESH TRACKS THERAPEUTICS, INC. (US) 2023-11-16 WO claimed
CN-116916929-A Novel use of pyrrolopyridine derivatives for the prevention or treatment of inflammatory diseases 株式会社沃若诺伊 2023-10-20 CN claimed
EP-4259153-A1 NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES Voronoi Inc. (KR) 2023-10-18 EP claimed
CN-115413278-A Novel pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same 丸仁制药株式会社 2022-11-29 CN claimed
EP-3604304-B1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) 2022-09-07 EP claimed
WO-2022123311-A1 NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES VORONOI CO., LTD. (KR) 2022-06-16 WO claimed
US-20220106307-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2022-04-07 US claimed
CN-113614086-A Pyrrolopyrimidine derivative and pharmaceutical composition for preventing or treating protein kinase-associated diseases comprising the same as active ingredient 沃若诺伊公司 2021-11-05 CN claimed
CN-113557237-A Pyrrolopyridine derivatives and use thereof for preventing or treating protein kinase-associated diseases 沃若诺伊公司 2021-10-26 CN claimed
WO-2020235973-A1 NOVEL USE OF PYRROLO-PYRIDINE DERIVATIVE COMPOUND FOR PREVENTION AND/OR TREATMENT OF CANCER 주식회사 보로노이 (KR) 2020-11-26 WO claimed
WO-2020036437-A1 SUBSTITUTED HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASES WHICH CONTAINS SAME AS ACTIVE INGREDIENT 재단법인 대구경북첨단의료산업진흥재단 2020-02-20 WO claimed
CN-110662745-A Pyrrolopyridine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating protein kinase-associated diseases comprising the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2020-01-07 CN claimed
WO-2018174650-A9 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES 재단법인 대구경북첨단의료산업진흥재단 2020-01-02 WO claimed
CN-106660955-B Cyclohexene derivative, preparation method and the pharmaceutical composition for being used to prevent or treat metabolic disease comprising it as active constituent 现代药品株式会社 2019-08-23 CN claimed
CN-106660955-A Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient 现代药品株式会社 2017-05-10 CN claimed
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US claimed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US claimed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP claimed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 SMN1; SMN2 2884/4885L3MBTL3 279/4885L3MBTL1 796/4885
US-20220106307-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DYRK1A, DYRK2, DYRK1B SMN1; SMN2 2702/4885L3MBTL3 4878/4885L3MBTL1 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.